Literature DB >> 10230868

Antinociceptive mechanism of Gosha-jinki-gan in streptozotocin-induced diabetic animals: role of nitric oxide in the periphery.

Y Suzuki1, K Goto, A Ishige, Y Komatsu, J Kamei.   

Abstract

Using streptozotocin-induced diabetic mice and rats, we evaluated the antinociceptive mechanism of Gosha-jinki-gan. The antinociceptive effect of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic mice, as determined by the tail-pressure test, was inhibited by N(G)-nitro-L-arginine methyl ester (L-NAME; 2, 5 mg/kg, i.p.). When L-NAME (10 microg) or methylene blue (500 microg) was topically administered to the intraplantar area of the hind paw, the region used for the paw-pressure test, the antinociceptive activity of Gosha-jinki-gan (0.3 g/kg, p.o.) in diabetic rats was decreased. These results suggested that the antinociceptive effect of Gosha-jinki-gan partly resulted from the peripheral action of increasingly produced nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10230868     DOI: 10.1254/jjp.79.387

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  14 in total

1.  Distribution of NADPH diaphorase-exhibiting primary afferent neurons in the trigeminal ganglion and mesencephalic trigeminal nucleus of the rabbit.

Authors:  Dalibor Kolesár; Mária Kolesárová; Andrea Schreiberová; Monika Lacková; Jozef Marsala
Journal:  Cell Mol Neurobiol       Date:  2006-06-14       Impact factor: 5.046

2.  Functional characterization of the geminiviral conserved late element (CLE) in uninfected tobacco.

Authors:  Christopher Ian Cazzonelli; John Burke; Jeff Velten
Journal:  Plant Mol Biol       Date:  2005-07       Impact factor: 4.076

3.  Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.

Authors:  Hiroi Kaku; Seisuke Kumagai; Hiroki Onoue; Anna Takada; Tadahiro Shoji; Fumiharu Miura; Akira Yoshizaki; Shinya Sato; Junzo Kigawa; Tsutomu Arai; Shinpei Tsunoda; Eiichiro Tominaga; Daisuke Aoki; Toru Sugiyama
Journal:  Exp Ther Med       Date:  2011-10-24       Impact factor: 2.447

4.  Gosha-jinki-gan (a Herbal Complex) Corrects Abnormal Insulin Signaling.

Authors:  Bolin Qin; Masaru Nagasaki; Ming Ren; Gustavo Bajotto; Yoshiharu Oshida; Yuzo Sato
Journal:  Evid Based Complement Alternat Med       Date:  2004-07-21       Impact factor: 2.629

5.  Ignavine: a novel allosteric modulator of the μ opioid receptor.

Authors:  Katsuya Ohbuchi; Chika Miyagi; Yasuyuki Suzuki; Yasuharu Mizuhara; Keita Mizuno; Yuji Omiya; Masahiro Yamamoto; Eiji Warabi; Yuka Sudo; Akinobu Yokoyama; Kanako Miyano; Takatsugu Hirokawa; Yasuhito Uezono
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

6.  An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.

Authors:  Keita Mizuno; Keisuke Shibata; Ryohei Komatsu; Yuji Omiya; Yoshio Kase; Schuichi Koizumi
Journal:  Cancer Biol Ther       Date:  2016-11       Impact factor: 4.742

7.  Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System.

Authors:  Shiying Jiang; Kousuke Baba; Keisuke Hagihara; Hideki Mochizuki; Tatsusada Okuno; Makoto Kinoshita; Chi-Jing Choong; Hideki Hayakawa; Hiroshi Sakiyama; Kensuke Ikenaka; Seiichi Nagano; Tsutomu Sasaki; Munehisa Shimamura; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2020-10-20       Impact factor: 7.620

8.  Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.

Authors:  Naohisa Yoshida; Toyoshi Hosokawa; Takeshi Ishikawa; Nobuaki Yagi; Satoshi Kokura; Yuji Naito; Masayoshi Nakanishi; Yukihito Kokuba; Eigo Otsuji; Haruo Kuroboshi; Masafumi Taniwaki; Tetsuya Taguchi; Hajime Hosoi; Terukazu Nakamura; Tsuneharu Miki
Journal:  J Oncol       Date:  2013-11-07       Impact factor: 4.375

9.  Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial.

Authors:  K Watanabe; A Shimada; K Miyaki; A Hirakata; K Matsuoka; K Omae; I Takei
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-09       Impact factor: 2.629

Review 10.  Kampo Medicines for Frailty in Locomotor Disease.

Authors:  Hajime Nakae; Yuko Hiroshima; Miwa Hebiguchi
Journal:  Front Nutr       Date:  2018-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.